High Throughput Combinatorial Formatting of PcrV Nanobodies for Efficient Potency Improvement

被引:21
作者
De Tavernier, Evelyn [1 ]
Detalle, Laurent [1 ]
Morizzo, Erika [1 ]
Roobrouck, Annelies [1 ]
De Taeye, Severine [1 ]
Rieger, Melanie [1 ,2 ]
Verhaeghe, Tom [1 ]
Correia, Andreia [1 ]
Van Hegelsom, Rob [1 ]
Figueirido, Rita [1 ,3 ]
Noens, Jeroen [1 ]
Steffensen, Soren [1 ]
Stohr, Thomas [1 ,4 ]
Van de Velde, Willem [1 ]
Depla, Erik [1 ,5 ]
Dombrecht, Bruno [1 ]
机构
[1] Ablynx NV, Technol Pk 21, B-9052 Ghent, Belgium
[2] Univ Hosp Munster, Inst Expt Musculoskeletal Med, Domagkstrasse 3, D-48149 Munster, Germany
[3] Immunocore Ltd, 90 Pk Dr,Milton Pk, Abingdon OX14 RY, Oxon, England
[4] A2M Pharma GmbH, Alfred Nobel Str 10, D-40789 Monheim, Germany
[5] VIB Discovery Sci, Gaston Geenslaan 1, B-3001 Leuven, Belgium
关键词
GRAM-NEGATIVE BACTERIA; PSEUDOMONAS-AERUGINOSA; III SECRETION; V-ANTIGEN; MURINE MODEL; INFECTION; PROTEIN; TRANSLOCATION; IMMUNIZATION; MACROPHAGES;
D O I
10.1074/jbc.M115.684241
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Improving potencies through concomitant blockage of multiple epitopes and avid binding by fusing multiple (different) monovalent Nanobody building blocks via linker sequences into one multivalent polypeptide chain is an elegant alternative to affinity maturation. We explored a large and random formatting library of bivalent (combinations of two identical) and biparatopic (combinations of two different) Nanobodies for functional blockade of Pseudonionas aeruginosa PcrV. PcrV is an essential part of the P. aeruginosa type III secretion system (T3SS), and its oligomeric nature allows for multiple complex binding and blocking options. The library screening yielded a large number of promising biparatopic lead candidates, revealing significant (and non-trivial) preferences in terms of Nanobody building block and epitope bin combinations and orientations. Excellent potencies were confirmed upon further characterization in two different P. aeruginosa T3SS- mediated cytotoxicity assays. Three biparatopic Nanobodies were evaluated in a lethal mouse P. aeruginosa challenge pneumonia model, conferring 100% survival upon prophylactic administration and reducing lung P. aeruginosa burden by up to 2 logs. At very low doses, they protected the mice from P. aeruginosa infection -related changes in lung histology, myeloperoxidase production, and lung weight. Importantly, the most potent Nanobody still conferred protection after therapeutic administration up to 24 h post -infection. The concept of screening such formatting libraries for potency improvement is applicable to other targets and biological therapeutic platforms.
引用
收藏
页码:15243 / 15255
页数:13
相关论文
共 39 条
[31]   Multi-functional characteristics of the Pseudomonas aeruginosa type III needle-tip protein, PcrV; comparison to orthologs in other Gram-negative bacteria [J].
Sato, Hiromi ;
Frank, Dara W. .
FRONTIERS IN MICROBIOLOGY, 2011, 2
[32]   Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury [J].
Sawa, T ;
Yahr, TL ;
Ohara, M ;
Kurahashi, K ;
Gropper, MA ;
Wiener-Kronish, JP ;
Frank, DW .
NATURE MEDICINE, 1999, 5 (04) :392-398
[33]   V-antigen homologs in pathogenic gram- negative bacteria [J].
Sawa, Teiji ;
Katoh, Hideya ;
Yasumoto, Hiroaki .
MICROBIOLOGY AND IMMUNOLOGY, 2014, 58 (05) :267-285
[34]   Anti-Pseudomonas aeruginosa serotype O11 LPS immunoglobulin M monoclonal antibody panobacumab (KBPA101) confers protection in a murine model of acute lung infection [J].
Secher, T. ;
Fauconnier, L. ;
Szade, A. ;
Rutschi, O. ;
Fas, S. C. ;
Ryffel, B. ;
Rudolf, M. P. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (05) :1100-1109
[35]   Therapeutic administration of anti-PcrV F(ab′)2 in sepsis associated with Pseudomonas aeruginosa [J].
Shime, N ;
Sawa, T ;
Fujimoto, J ;
Faure, K ;
Allmond, LR ;
Karaca, T ;
Swanson, BL ;
Spack, EG ;
Wiener-Kronish, JP .
JOURNAL OF IMMUNOLOGY, 2001, 167 (10) :5880-5886
[36]  
Stryjewski ME, 2003, P C C I D, V7, P1
[37]   Polarisation of type III translocation by Pseudomonas aeruginosa requires PcrG, PcrV and PopN [J].
Sundin, C ;
Thelaus, J ;
Bröms, JE ;
Forsberg, Å .
MICROBIAL PATHOGENESIS, 2004, 37 (06) :313-322
[38]   Protective Effect of Different Anti-Rabies Virus VHH Constructs against Rabies Disease in Mice [J].
Terryn, Sanne ;
Francart, Aurelie ;
Lamoral, Sophie ;
Hultberg, Anna ;
Rommelaere, Heidi ;
Wittelsberger, Angela ;
Callewaert, Filip ;
Stohr, Thomas ;
Meerschaert, Kris ;
Ottevaere, Ingrid ;
Stortelers, Catelijne ;
Vanlandschoot, Peter ;
Kalai, Michael ;
Van Gucht, Steven .
PLOS ONE, 2014, 9 (10)
[39]   A Novel Anti-PcrV Antibody Providing Enhanced Protection against Pseudomonas aeruginosa in Multiple Animal Infection Models [J].
Warrener, Paul ;
Varkey, Reena ;
Bonnell, Jessica C. ;
DiGiandomenico, Antonio ;
Camara, Maria ;
Cook, Kimberly ;
Peng, Li ;
Zha, Jingying ;
Chowdury, Partha ;
Sellman, Bret ;
Stover, Kendall .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (08) :4384-4391